Pharmaceutical - Diabetes, Licensing


Current filters:


Popular Filters

1 to 25 of 43 results

Ferring Pharma regains rights to DDAVP portfolio

Ferring Pharma regains rights to DDAVP portfolio


Privately-held Switzerland-headquartered Ferring Pharmaceuticals says it has acquired DDAVP (desmopressin…

DDAVPDiabetesFerring PharmaceuticalsGenito-urinaryLicensingPharmaceuticalSanofiSwitzerland

Islet and BHV sign licensing agreement for diabetes drug in development

Islet and BHV sign licensing agreement for diabetes drug in development


Metabolic biopharma specialist Islet Sciences says that its merger partner, Brighthaven Ventures (BHV…

BHVBrazilBrighthaven VenturesDiabetesIslet SciencesLicensingPharmaceuticalremogliflozin

Sanofi in $925 million deal to commercialize MannKind’s Afrezza

Sanofi in $925 million deal to commercialize MannKind’s Afrezza


French pharma major Sanofi has entered into a worldwide exclusive licensing agreement with the USA’s…

AfrezzaDiabetesGlobalInsulin therapyLicensingMannKindPeptide hormonesPharmaceuticalSanofi

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate


Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

Ligand licenses five programs to Viking Therapeutics


US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate


US pharma giant Merck & Co and South Korea’s Samsung Bioepis have expanded their collaboration with…

BiosimilarsDiabetesInsulin Glargine [rDNA origin] InjectionLantusLicensingMerck & CoPharmaceuticalResearchSamsung BioepisSanofi

Chinese, European drugmakers strike $500 million-plus deal


An agreement worth more than $500 million between privately-held Swiss/Greek pharmaceutical and clinical…

DiabetesEuropeFochon PharmaFosun PharmaLicensingPharmaceuticalResearchSellas Life Sciences

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal


PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Evolva to license EV-077 to Serodus


Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Depomed expands geographic scope of metformin deal with Merck


USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

ThromboGenics gains rights to DME drug


Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Sirona Biochem signs LoI with leading Chinese diabetes company


Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Adocia re-acquires exclusive rights to insulin analog from US drug major


French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Eli Lilly exercises rights to diabetes drug candidate TT-401 from Transition Therapeutics


Canada's Transition Therapeutics (TSX: TTH) announced this morning (June 17) that US drug major Eli Lilly…

DiabetesEli LillyLicensingPharmaceuticalTransition TherapeuticsTT-401

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research


Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Abide Therapeutics in up to $430 million deal with Merck & Co for type 2 diabetes and metabolic disease


Privately-held biopharma firm Abide Therapeutics has entered into a collaboration agreement with US…

Abide TherapeuticsDiabetesLicensingMerck & CoMetabolicsPharmaceuticalResearch

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Emisphere earns $10 million on amended deal with Novo Nordisk


USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Merck KGaA links with Bristol-Myers for Glucophage promotion in China


German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin


US drug major Eli Lilly (NYSE: LLY) and German independent drugmaker Boehringer Ingelheim said yesterday…

Boehringer IngelheimDiabetesEli LillyempagliflozinLicensingLY2605541PharmaceuticalResearch

1 to 25 of 43 results

Back to top